Loading...
Biochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy.
Tran, Anna T Mandall, P Swindell, Ric Hoskin, P Bottomley, D Logue, John P Wylie, James P
Tran, Anna T
Mandall, P
Swindell, Ric
Hoskin, P
Bottomley, D
Logue, John P
Wylie, James P
Citations
Altmetric:
Abstract
Routine use of I-125 interstitial brachytherapy (BT) alone in intermediate risk (IR) prostate cancer is controversial. It is often combined with external beam radiotherapy (EBRT). The biochemical outcome of a large cohort of only IR disease treated with BT monotherapy is reported.
Description
Date
2013-07-09
Publisher
Collections
Keywords
Type
Article
Citation
Biochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy. 2013: Radiother Oncol